Skip to Main Content

File this under “Who’da thunk it?”

In a surprising development, Merck reported that a cholesterol-lowering drug met its primary goals in a trial that was measuring cardiovascular outcomes. The reason this comes as a surprise is that the type of medicine being studied has repeatedly failed when other drug makers pursued their own versions.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!